Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease.

ABSTRACT: Base editors can correct disease-causing genetic variants. After a neonate had received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency, a disease with an estimated 50% mortality in early infancy, we immediately began to develop a customized lipid nanoparticle-delivered base-editing therapy. After regulatory approval had been obtained for the therapy, the patient received two infusions at approximately 7 and 8 months of age. In the 7 weeks after the initial infusion, the patient was able to receive an increased amount of dietary protein and a reduced dose of a nitrogen-scavenger medication to half the starting dose, without unacceptable adverse events and despite viral illnesses. No serious adverse events occurred. Longer follow-up is warranted to assess safety and effica

SUBMITTER: Musunuru K 

PROVIDER: S-EPMC12713542 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature